3 indigenous players in clearance phase-2; Apollo 11 moment for India: Niti Aayog's VK Paul
VK Paul says globally, 33 vaccines are in clinical trial phase, of which 10 vaccines are in advanced trial phase. Key consideration while prioritising population for vaccine inoculation is accessing people with risk to mortality and protection of healthcare system and response system
- Dec 13, 2020,
- Updated Dec 13, 2020 3:12 PM IST
NITI Aayog member Dr VK Paul has said three of the top 10 global vaccine candidates are from India and these companies will not only produce vaccines for the country but for the entire world. Addressing a session on 'Vaccine Magic and Re-imagining Healthcare in a Post-COVID World', organised during FICCI's 93rd Annual Convention, Dr Paul said there will be no pressure on the drug regulator on the COVID-19 vaccine approval and the final call will be made on scientific principles.
He said globally, 33 vaccines are in the clinical trial phase out of which 10 vaccines are in the advanced trial phase. "Three Indian vaccines are part of the top 10 global players. It is a proud moment to say that the key three indigenous players -- Bharat Biotech-ICMR, Zydus Cadila and Serum Institute-AstraZeneca -- are in clearance phase-2, which has created an Apollo 11 moment for India," said Dr Paul.
NITI Aayog member Dr VK Paul has said three of the top 10 global vaccine candidates are from India and these companies will not only produce vaccines for the country but for the entire world. Addressing a session on 'Vaccine Magic and Re-imagining Healthcare in a Post-COVID World', organised during FICCI's 93rd Annual Convention, Dr Paul said there will be no pressure on the drug regulator on the COVID-19 vaccine approval and the final call will be made on scientific principles.
He said globally, 33 vaccines are in the clinical trial phase out of which 10 vaccines are in the advanced trial phase. "Three Indian vaccines are part of the top 10 global players. It is a proud moment to say that the key three indigenous players -- Bharat Biotech-ICMR, Zydus Cadila and Serum Institute-AstraZeneca -- are in clearance phase-2, which has created an Apollo 11 moment for India," said Dr Paul.